Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7472523 | 1.00 | SLC10A2 (0.63) | SLC10A2 | |
| SCHEMBL7472527 | 1.00 | SLC10A2 (0.63) | SLC10A2 | |
| SCHEMBL2582109 | 1.00 | SLC10A2 (0.63) | SLC10A2 | |
| SCHEMBL19170512 | 0.92 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL1388882 | 0.92 | SLC10A2 (0.54) | SLC10A2 | |
| SCHEMBL2590911 | 0.92 | SLC10A2 (0.54) | SLC10A2 | |
| SCHEMBL2586789 | 0.92 | SLC10A2 (0.54) | SLC10A2 | |
| SCHEMBL2585255 | 0.92 | SLC10A2 (0.56) | SLC10A2 | |
| SCHEMBL7470516 | 0.91 | SLC10A2 (0.53) | SLC10A2 | |
| SCHEMBL1387665 | 0.91 | SLC10A2 (0.55) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114096268-A | Methods for increasing growth in pediatric subjects with cholestatic liver disease | 米鲁姆制药公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-114072153-A | Methods for treating cholestasis | 米鲁姆制药公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114072152-A | Genotype and dose-dependent response to ASBTI in patients with bile salt efflux pump deficiency | 米鲁姆制药公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3923943-A1 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | Mirum Pharmaceuticals, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020167964-A1 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | MIRUM PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-10251880-B2 | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions | SATIOGEN PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-2968230-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968262-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015065983-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS | Lumena Pharmaceuticals, Inc. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20150087642-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS, INC. | 2015-03-26 | — | — | US | disclosed |
| EP-2575821-A2 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | Satiogen Pharmaceuticals, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2563122-A1 | CHEMICAL COMPOUNDS | Glaxosmithkline LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2013020108-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PANCREATITIS | Lumena Pharmaceuticals, Inc. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2011150286-A2 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS,INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011137135-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | WO | disclosed |
| EP-0775126-B1 | HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES | WELLCOME FOUND (GB) | 2002-10-30 | — | — | EP | disclosed |
| EP-1203769-A1 | Hypolipidemic 1,4-benzothiazepine derivative | THE WELLCOME FOUNDATION LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| EP-1140187-A1 | COMBINATIONS FOR CARDIOVASCULAR INDICATIONS | G.D. Searle LLC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038725-A1 | COMBINATIONS FOR CARDIOVASCULAR INDICATIONS | G.D. SEARLE LLC (US) | 2000-07-06 | — | — | WO | disclosed |
| US-5910494-A | NOVEL COMPOUNDS THAT REDUCE THE ABSORPTION OF BILE ACIDS FROM THE INTESTINE; FOR PROPHYLAXIS AND TREATMENT OF HYPERLIPIDEMIC CONDITIONS, SUCH AS ATHEROSCLEROSIS | GLAXO WELLCOME INC. (US) | 1999-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251880-B2 | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions | SLC10A2, GPR119, GPBAR1 | SLC10A2 1/4885 |
| US-20150087642-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SLC10A2, GPR119, GPBAR1 | SLC10A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.